

INDEX

A

- Accuracy
 - clinical research data 309
 - diagnostic tests 132–133
- Additive models, interaction in. *See* Interaction
- Address transparency 256
- ADL and Barthel index 156
- Alignment of research questions 300
- Allele-sharing method 191–194
- Allocation concealment 6, 98
- Allocative efficiency 237–239, 241
- Alpha spending 117
- Analyses
 - hypothesis-generating 125–126
 - interim 117–119
 - planned 105
 - subgroup 106
- ANOVA 65, 91
- Appraisal of Guidelines, Research, and Evaluation
 - (AGREE) Collaboration 258
- Argument 40
- Ascertainment bias 173–174
- Association studies, for genetic identification 195–199
- Audit trail 106–107

B

- Bare metal coronary artery stents (BMS) 276
- Belmont Report 286
- Berlin Code of 1900 285
- Bias, in clinical epidemiologic studies 3, 173
 - ascertainment bias 23
 - Case-mix bias 24
 - competing risk bias 174, 175
 - compliance bias 179
 - contamination bias 179, 180
 - diagnostic bias 177, 178
 - family information bias 179
 - leak time bias 177
 - length time bias 177
 - volunteers bias 174, 175
 - in clinical studies 13
 - in different designs 180–181
 - dose-targeting bias 25
 - by indication 25

- information bias 29
- loss to follow-up bias 175, 181
- minimizing methods of 181–182
- nonresponse bias 175, 181
- overmatching bias 176
- recall/memory bias 176–177
- sampling bias 6, 29
 - types of
 - confounding bias 180
 - information bias 176–179
 - intervention (exposure) bias 173, 179–180
 - selection bias 24, 25, 173–176

Biomarkers

- confounding 144–145
- continuous 147–148
- defined 138
- diagnostic 140–141, 146–147
- sample size 148
- dichotomous 147
- generalizeability of 148–149
- HMG-CoA inhibitors 141
- in interventional studies 141
- prognostic 139–140
 - cohort study of 142–143
 - sample size 145–146
 - survival analysis of 143–144
- risk factors, relationship with 138–139
- surrogate outcomes 149–153
- Biospecimen collection 309
- Blinding 100–101
- Blocking 98
- Budgets
 - direct costs 302–304
 - indirect costs 304

C

- Canadian Agency for Drugs and Technologies
 - in Health (CADTH) 265
- Canadian health care system 300
- Canadian hypertension education program 259
- Canadian institutes of health research
 - (CIHR) 300
- Canadian Research Ethics Boards 287
- Candidate surrogate outcomes 8
- Case-control design, in association studies 196–197

Case-control studies.....	12, 27
advantages of.....	28
design of.....	28, 30
selection of controls.....	30
problems associated with design.....	28
of information bias.....	29
issue of confounding variables.....	29
sampling bias.....	29
Case study.....	
diagnostic tests.....	129–130
health technology assessment.....	276–279
Censoring.....	74, 119–120
Children, ethical research on.....	295–296
Chronic kidney disease (CKD).....	5
CI. <i>See</i> Confidence intervals	
CINAHL. <i>See</i> Cumulative Index to Nursing and Allied Health Literature	
Classical test theory.....	167. <i>See also</i> Patient-reported outcomes
Clinical practice guidelines.....	251
committee.....	253
evaluation of.....	258–259
guideline and target audience.....	252–253
implementation strategy.....	257–258
legal issues.....	260
principles of development.....	252
revision.....	259
Clinical relevance.....	2, 11, 145, 172, 184
Clinical research.....	
budget estimation.....	302–304
cohort study.....	142
funding/grants.....	300–302
goal.....	3
investigators, travel for.....	303
management of.....	305–310
reporting governance in.....	304–305
staff, training for.....	307
clinical studies, precision and accuracy in.....	4
Clinical trials.....	
censoring.....	119–120
in economic evaluation.....	242–244
of end-stage renal disease.....	243
in ethical research.....	291–294
financial interest declaration.....	294
of health care costs.....	243–244
limitations of.....	247
planning.....	247–248
Clustered data.....	79
Cohort studies.....	20–21
advantages of.....	21–22
to check disease status.....	146–147
designing of.....	25
confounding variables.....	26–27
control group selection.....	27
data collection.....	26
period prevalent cohort.....	26
prevalent <i>vs.</i> incident cohorts.....	25–26
disadvantages of.....	22–25
of prognostic biomarkers.....	142–143
Collaborative health research projects (CHRP) program.....	300–301
Colorectal cancer.....	174, 179
Common rule, United States.....	287
Competing risk events. <i>See</i> Competing risks bias	
Competing risks bias.....	174
Complex genetic diseases.....	
determination of.....	188–189
gene identification strategies.....	
association analysis in.....	195–199
linkage methods in.....	190–195
mode of inheritance, determination of.....	189–190
Compliance bias.....	179
Composite outcomes.....	120–121
Confidence intervals.....	34, 35, 60, 66
Confidentiality.....	
data.....	288
privacy and.....	293
Conflict of interest.....	256–257
Confounding bias.....	173, 180
minimizing methods.....	182–184
Confounding biomarkers.....	144–145
Confounding variables.....	29
CONSORT trials (Consolidated Standards of Reporting Trials).....	110
Construct validity.....	8, 165
Consumables.....	108, 302
individual expenses.....	303
Contamination bias.....	179, 180
Contamination of groups, in cohort study.....	23
intention-to-treat fashion, analysis of data.....	23
treatment-as-received” manner.....	24
Content or face validity.....	165
Correlated data.....	79
Correlation structures.....	83
Cost-benefit analysis (CBA).....	272–273
Cost-effectiveness analysis (CEA).....	238–239, 272–273
of health technologies.....	264
in HTA.....	264–265
Costs.....	
of CPG development.....	259
of diagnostic tests.....	134–135
of health care.....	244
minimization analysis.....	239
Cost-utility analysis (CUA).....	239–240, 273–274
Cox proportional hazards method.....	33
Cox regression model.....	145
Cox’s model.....	59, 77, 78, 88
check for model.....	79

coefficients in Cox's regression 78
 effect (β) of covariate in 90
 variations of 86

CPG. *See* Clinical practice guidelines

CRC. *See* Colorectal cancer

Criterion validity 165

Critical appraisal 110, 204, 254

Critical turning points, in substantive theory 209–210

Crossover design 14, 100, 122–123

Cross-sectional studies 12, 15, 20, 80, 181

Cumulative index to nursing and allied health literature 225

D

Database, bibliographic
 of HTA resources 267–268
 language and vocabulary used in 269–270

Data collection
 in clinical research 309–310
 for HCA 270–271
 in randomized control trial 105

Data safety and monitoring committee 109

DCCT. *See* Diabetes control and complications trial

DCOR clinical trial 243

Decision analysis 171, 244, 247

Decision maker
 in health care 263
 role of
 cost—utility analysis 239
 economic analysis 264
 research design 135

Decision trees 274

Derivation set 149

Diabetes control and complications trial 114, 115, 118

Diagnostic bias 177–178

Diagnostic odds ratio (DOR) 133

Diagnostic spectrum effect 148

Diagnostic tests
 accuracy 132–133
 assessment of 15
 case study 129–130
 costs 134–135
 gold standard 128
 likelihood ratio 130–132
 predictive values of 129
 research design 133–135
 sensitivity and specificity of 128–129

Direct association studies 195.
See also Gene identification strategies

Direct costs 302–304

Drop-in effects 105, 107

Dropout 75, 105, 107, 145

Drug-eluting stents (DES), Canada 276

E

ECONOLIT database, importance of 225–226

Economic analysis
 checklist 274
 conducted by PATH 277
 in HTA 272
 risk reduction 123

Economic evaluation 236
 clinical trials 242–244
 for incremental costs and benefits of technology 272
 PATH presentation 278
 problem associated with 247
 results interpretation 240–242
 strengths and weaknesses of 242–244
 types of 238–240

Economic issues 106

EMBASE and MEDLINE, differences of 225

Endophenotype-based approach, role of 196

End-point adjudication committee 109

End-stage renal disease 205, 235
 grounded theory study for 206–211
 clinical trials of 243
 cost-effectiveness analysis of 239

Equipments
 additional 304
 required 303

Errors
 accidental 3
 alpha error 7
 effect on study results 5
 measurement 8
 random 3, 173
 systematic error 3, 5, 40, 90, 172, 173
 type I and type II, in clinical trial 30–31, 103
 types of 3

ESRD. *See* End-stage renal disease

European Regulatory Issues on Quality
 of Life Assessment Group 159

European Union, HRQOL guidelines 158–159

Evidence-based research, key elements of 299

Evidence interpretation 271

Evidence tables, used in CPG 255

Exposed *vs.* unexposed subjects 23

Extended generalized linear models 80
 choice of analytical tool 90–91
 for data 84–85
 correcting model variance 83–84
 exchangeable 83
 generalized estimating equations 84
 fixed effects 80–81
 intraclass correlation coefficient 82
 mixed effect models, for fixed and random effects 82
 panel data layout 80
 variance components, of data 81–82

- Extended survival models 85–86
 correlation among events, violating
 assumption 86
 correlation in survival times 85
 event dependence within subject 86
 risk set, for survival analysis 86
 ordered events 87–88
 time-dependent effects 88
 time-varying covariate 89
 unordered events 86–87
 shared frailty 86
 unshared frailty 85–86
 External validity 8, 10, 11, 25, 27, 182
- F**
- Factorial designs 14, 99, 105, 122
 Family information bias 179
 Final outcome 9, 178
 Follow-up
 outcome measures 102
 rate of loss 107–108
 time to complete 143
 Food and Drug Administration (FDA), U.S. 158
 Foundations. *See also* Funding
 charitable or not-for-profit agencies 301
 private and public, for research grants 301
 Frailty model 89–91. *See also* Extended
 generalized linear models
 Function, concept of 40
 Funding
 for clinical research 300–302
 costs 108
 distribution 307
 license required for 108
 sources of 108–109
- G**
- Gene identification strategies
 association analysis in 195–199
 linkage methods in 190–195
 Generalized linear models
 characteristics and conditions of validity of 65
 limitation, for use 66
 members, attributes in 62–63
 regression coefficients 65–66
 standard link functions and inverses 63
 systematic component of 64
 Genetic association study 196
 interpretation of 198–199
 Genetic diseases, clinical epidemiologic studies in
 bias in different designs 180–181
 bias minimizing methods in 181–182
 confounding minimizing strategies in 182–184
 qualitative research methods in 203–204
 grounded theory methodology 205–211
 qualitative database in scale
 construction 211–215
 types of bias in
 confounding bias 180
 information bias 176–179
 intervention (exposure) bias 179–180
 selection bias 173–176
 Genetic epidemiology, in complex traits 187–188
 determination of 188–189
 gene identification strategies
 association analysis in 195–199
 linkage methods in 190–195
 mode of inheritance, determination of 189–190
 Genetic equilibrium. *See* Hardy-Weinberg equilibrium
 Genetic heterogeneity 193, 194
 Genome Canada 301, 305
 Genomewide association studies 188, 197
 Genomic imprinting 189, 190
 Good Clinical Practice (GCP) 287
 membership guidelines 288–289
 Governance
 of ethics review 287–288
 policies 287–288
 reporting 304–305
 Grades of recommendation assessment, development
 and evaluation (GRADE) 254, 255
 Grading, clinical practice guideline 254–255
 Grants
 budget allocation 304–305
 clinical research 300–302
 review 290
 Gray literature 268–269
 Grounded theory methodology 205–206
 in substantive theory generation 206–211
 Group sequential methods 117
- H**
- Hard outcomes 8
 Hardy-Weinberg equilibrium 197–198
 Hazards proportionality 78. *See also* Cox's model
 Health care
 costs 244
 decision makers 263
 funding 242
 impact of the therapy on costs of 236
 and medical devices 264
 policy 265
 problems 96
 public financing of 156
 technologies (*see* Health technology assessment)
 Health economics 236–237
 Health outcomes 16, 171, 203, 210, 237, 247,
 253, 258, 266, 273

Health-related quality of life157–159, 240
 criteria for evaluation 160
 domains for general measures 162
 instruments used for 161
 SF-6D and versions 162–163
 guidance document, for measurement 159–160
 Health status 113, 156, 157, 160, 163, 209, 210,
 273, 293
 Health technology assessment
 basic framework for 266–270
 cost-benefit analysis in 273
 cost-effectiveness analysis in 264–265, 272–273
 cost-utility analysis in 273–274
 data collection 270–271
 defined 265
 dissemination strategies 275
 economic analysis in 272
 evidence interpretation in 271
 identifying topics 266
 Health Utilities Index 240
 Healthy years equivalent (HYE) 273
 Heart outcomes prevention evaluation (HOPE) 99, 110
 Helsinki Declaration 286
 Hemodialysis, grounded theory study for 206–211
 Hereditary nonpolyposis colorectal cancer 205
 Hierarchy of evidence 11, 22
 Historical cohort 21, 22, 25
 HNPCC. *See* Hereditary nonpolyposis colorectal cancer
 HRQOL. *See* Health-related quality of life
 HTA. *See* Health technology assessment
 HTA reports 275
 Hypothesis-generating analyses 125–126

I

IBD. *See* Identical by descent
 ICD therapy. *See* Implantable cardioverter-defibrillator
 therapy
 Identical by descent 192
 Identity link function 63
 Implantable cardioverter-defibrillator therapy 176
 Incidence rate ratio 57–58
 Incompetence, and ethical research 405
 Indirect association studies 195. *See also* Gene
 identification strategies
 Indirect costs 304
 Information bias 173. *See also* Bias,
 in clinical epidemiologic studies
 in case-control studies 29
 diagnostic bias 177–178
 family information bias 179
 lead-time and length-time bias 177
 minimizing risk of 26, 182
 recall or memory bias 176–177
 Will Rogers phenomenon 178–179

Informed consent 96, 164, 207, 286, 291–296
 Input and output
 possible relationships between 52
 variables measurement 7
 Intention-to-treat analysis 6, 103
 Interaction 53
 coefficient of 56
 modeling confounding and 53–54
 in multiplicative models 56–57
 hypothetical cardiac events data as IRR 57–58
 parameter as measure of 55
 statistical meaning 54–55
 Interest phenomenon 8–9
 Interim analyses 106, 117–119
 Intermediate (surrogate) response 9
 Intermediate variables 8, 51–52, 51–53
 Internal validity 8, 10, 11, 23, 24, 271
 Intervention bias 173, 179
 Intervention questions, experimental
 design for 13–14
 IRR. *See* Incidence rate ratio
 Item response theory 167

K

Kaplan-Meier (K-M) analysis 144
 Kaplan-Meier method 32, 36
 Karnofsky performance status 156

L

Latent trait theory 167
 LD. *See* Linkage disequilibrium
 Lead-time bias 173, 177, 178
 Leber's optic atrophy 190
 Legal issues
 in CPG development 260
 in research ethics 288
 Length-time bias 177, 178
 LESRD-H. *See* Living with end-stage renal
 disease and hemodialysis
 Level of evidence
 in diagnostic studies 15
 meta-analysis of randomized controlled trials for 221
 of observational studies 255
 sample sizes and follow-up for 120
 Level of significance 7, 195
 Licensing, for drugs/health technologies 264
 Likelihood
 of article being valid 240
 based estimation procedures 145
 of CKD 6
 as function of recombination fraction 191
 and probability 44
 ratio 130–133, 135, 191, 192
 treatment being successful 242

- Linear model 45, 47–51, 53, 62, 65, 67, 68, 70.
See also Generalized linear models
 regression coefficients of 65
 three-dimensional representation 51
- Linear predictor 41, 47, 49, 56, 58, 63, 67, 70, 77, 81, 82
- Linear regression 35, 42, 43, 47, 64, 67, 68, 70, 183
- Linear relationship 42, 45, 47
- Linkage disequilibrium 195–197
- Linkage methods, for genetic identification 190–195
- Literature review. *See also* Systematic review
 in clinical trials 97
 in development of CPG 253
 of HTA resources 267
 to identify related research 2
- Living with end-stage renal disease and
 hemodialysis 208–209
- Logistic function 41, 63, 66–68
- Logistic model. *See also* Poisson model, for count
 check, for model fail 70–71
 coefficient in logistic regression 68–70
 structure of 66
 binary nature of response 66
 at dichotomous response 68
vs. linear model 67–68
 sigmoid nature and information of error 67
- Logit function 63
- Longitudinal cohort studies 12
- Longitudinal data 39, 79, 80, 92
- Longitudinal genetic epidemiology 25.
See also Genetic epidemiology
- Longitudinal studies 12, 20, 61, 62, 70, 79, 92
 analyzing confounders 33
 to assess diagnostic tests 16
 computation of CI for 35
 confounding variables, controlling for 35–36
 null hypothesis for OR or RR 34
 quantitative estimate of risk 33–34
 relative risk and odds ratio, calculation of 34
 survival data analysis 36
 multivariate regression techniques 36–37
- LP. *See* Linear predictor
- M**
- Markov models 274
- Masking 8, 100, 227
- Matching, in confounding improvement 182–183
- Maximum likelihood estimation 43, 44, 72, 73, 79.
See also Likelihood
- Measurement bias. *See* Information bias
- Memorandum of understanding (MOU) 308
- Memorial University of Newfoundland,
 research grant report 302
- Memorial University, research ethics board 289
- Mental component summary (MCS) 161
- Meta-analysis 218, 272
 and systematic review
 advantages of 220–222
 limitations of 222–223
 scientific quality assessment 223–229
- Microsatellite markers, advantage of 192–193
- Ministry of Health and Long-Term Care (MOHLTC),
 Ontario 276
 Medical Advisory Secretariat (MAS) 277, 278
- Missing data 8, 14, 22–23, 92, 100, 168
- MLE. *See* Maximum likelihood estimation
- Model-independent. *See* Allele-sharing method
- Modifiers 8
- Mortality, clinical outcomes 119–120
- Multicollinearity 79
- Multiple measurements 62
- Multivariable model (R^2 statistics), GFR cohort study 64
- Multivariate ANOVA (MANOVA) 92
- Multivariate modeling
 to assess independence and freedom
 from confounding in 142
 of cohort studies 143
 in confounding improvement 183
- Multivariate regression techniques 36–37
- N**
- Narrative reviews and systematic review,
 difference of 218–220
- National Health and Medical Research Council
 of Australia 252
- National Institute for Clinical Excellence, U.K. 242, 253
- National Institutes of Health, U.S. 108, 300
- National Library of Medicine (NLM), U.S. 267
- National Research Act (1974) 286
- Natural log links 64
- Nested case-control studies 28
- Networking, and clinical research 309
- Neutral trials 123
- NIDDM. *See* Non-insulin-dependent diabetes
- Non-insulin-dependent diabetes 110, 194
- Noninterventional/observational studies 20
- Nonparametric method. *See* Allele-sharing method
- Nonparticipants 24, 228. *See also* Participants
- Normally distributed errors 3. *See also* Errors
- Number needed to treat 123
- Nuremberg Code 285–286
- O**
- O'Brien and Fleming method 118
- Observational-experimental discrepancy 125
- Observational studies 30
 power and sample size estimation 30–33
 proportion in exposed group, calculation 31–32
 require sample size, factors influencing 31

sample size for Cox Proportional Hazards model.....	33
sample size for Long-Rank test.....	32
type I and type II errors, probability of.....	30–31
Odds ratio	31, 34, 35, 48, 69, 70, 141, 149
Ontario health care system	277
Ontario Health Technology Advisory Committee (OHTAC).....	278
recommendations.....	278–279
Open-label run-in periods, and clinical trials	121
Opportunity costs.....	237
OR. <i>See</i> Odds ratio	
P	
Panel data 80	
Parametric method. <i>See</i> Recombinant-based method	
Participants	
confirming interpretive summaries	208
in control trial.....	105
delaying enrollment.....	100
demographic data for identification.....	288
to enroll eligible.....	107
entering in RCT and null hypothesis	102
identified based on disease.....	12
monitoring.....	62
on a quantitative scale.....	150
research.....	292, 293
selection.....	4, 181, 205
Patient Perception of Hemodialysis Scale	211
Patient-reported outcomes	155. <i>See also</i>
Health-related quality of life	
comparing groups and assessing changes.....	167–168
to comprise validity.....	165
emphasis on positive health	156
focus groups and professional facilitators, role in.....	163–164
forms and questionnaires, use of.....	155
health status and functional status	157
HRQOL claims.....	158
and individual's observation of experience	157
measurement quality of life, at societal level.....	156
to measure subjective experience.....	163
models for assessment.....	157
scale's reliability, estimation of	166–167
scales to discriminate individuals	164
supporting claims of therapeutic benefit in.....	158
technocratic approach to public policy.....	156
utility of intermediate outcome	158
Patients, interventions, controls, and outcomes.....	2, 3, 10, 269
Peer-review, of research ethics	290
Personnel	
agreements with department/institution	308
costs, salary and benefits.....	302–303
training.....	307
Pharmaceutical manufacturers	
economic evaluations of drugs, role in.....	242–243
licensing of drugs, role in.....	264
relationship with guidelines committees.....	256
Physical Component Summary (PCS).....	161
PICO. <i>See</i> Patients, interventions, controls, and outcomes	
PICO(S) model, for development of search strategy	269–270
Planning	
in clinical trials	101, 247–248
of health services.....	237
in prognostic biomarker study	143–145
Poisson distributions.....	44, 49, 64, 72, 73
Poisson model, for count	71
check for model fail	73–74
coefficient meaning in	73
structure of.....	72–73
likelihood function of λ	73
MLEs of β parameters.....	72
model offset.....	72
Poisson regression.....	49, 56, 62, 64, 71, 72
goodness-of-fit test for	73–74
using Framingham data	73
Policies	
ethical review.....	287
governance.....	287–288
Population	
and clinical trial	102–103
and diagnostic test	134
Positional cloning, 190–191. <i>See also</i> Genetic epidemiology, in complex traits	
PPHS. <i>See</i> Patient Perception of Hemodialysis Scale	
Prader-Willi syndrome	190
Precision ratio.....	269
Predictive values, for diagnostic tests.....	129
Prentice criterion, to determine surrogate endpoint.....	151–152
Prevalence-incidence (Neyman) bias	175–176
Privacy data	288
Private industry, clinical research grant.....	301
Professional organizations, clinical research grant.....	301–302
Proficiency bias.....	179
Programs for assessment of technology in health (PATH)	276
Proportional hazards model.....	77–78
Pseudo-R ² for nonlinear models.....	70
Public Health Service, U.S.....	286
Public relations, importance of.....	309
PULSES profile	156
P value.....	7, 11, 31, 33, 54, 59, 66, 106, 117, 194, 196, 199

Q

QLI. *See* Quality of life instrument

Quality

- clinical data..... 243
- clinical evidence..... 254
- of CPG document..... 258

Quality-adjusted life years (QALYs)

- cost analysis..... 239–240
- and CUA..... 273

Quality control..... 11, 106, 309

Quality of life, health-related. *See* Health-related quality of life (HRQOL)

Quality of life instrument..... 213

Questionnaires..... 155, 157, 163, 259, 292, 307, 308

QUORUM methods..... 270

R

Random effect models..... 80, 82, 85, 91

Randomization..... 16

- adaptive..... 99–100
- audit..... 106–107
- blinding..... 100–101
- block (*see* Blocking)
- cluster..... 98–99
- controlled trial..... 95–96
- economic issues..... 106
- factorial design of..... 99, 122
- imbalanced..... 124
- multicenter..... 101
- neutral..... 123
- noninferiority..... 100
- one-tailed, trial design..... 115
- planning
 - allocations and interventions..... 101
 - inclusion and exclusion criteria..... 101
- risk factors..... 124–125
- stratified..... 98, 122–123
- subjects, characteristics of..... 115–116
- surrogate markers of..... 125
- trial design

Randomized controlled trials..... 11, 19. *See also* Randomization

- design appropriateness for assessment of..... 13
- parallel trial..... 14

Random sample..... 5, 149

Random sequences generation..... 6

Rasch models..... 167

RCTs. *See* Randomized controlled trials

Recall ratio..... 269

Receiver operating characteristic (ROC) curve..... 132–133

Recombinant-based method..... 191, 192, 194

Recombination fraction..... 191, 192. *See also* Genetic epidemiology, in complex traits

Recruitment rate..... 104

Reference Manager®..... 270

Referral bias. *See* Ascertainment bias

RefWorks®..... 270

Regression method of analysis

- estimation purpose..... 42
- intercept (β_0)..... 42
- likelihood and probability..... 44–45
- maximum likelihood estimation (MLE)..... 43–44
- ordinary least square method..... 43
- parameter estimates..... 42

Relative risks..... 22, 31, 34–36, 70, 78, 145, 240

Reliability coefficients..... 166

RENAAL clinical trial..... 110

Repeated measures..... 79

Reporting

- in clinical research..... 110, 304–305
- for proper interpretation and evaluation..... 16

Research design, for diagnostic test..... 133–135

Research ethics..... 285–287

- application
 - signature page..... 294
 - clinical trials in..... 291–294
 - governance of..... 287–288
 - inclusiveness in..... 295–296
 - informed consent..... 291–294
 - privacy and confidentiality of..... 288
 - sample study..... 94

Research ethics board (REB)

- functions of..... 289–290
- of Memorial University..... 289
- risks and benefits, review of..... 290

Research participants, ethical

- practical tips for..... 296
- privacy rights..... 293
- responsibilities of..... 292–293
- withdrawal procedure..... 293

Research plan, clinical implementation of..... 308–309

Restriction, in confounding improvement..... 182

Review committees, ethical..... 287. *See also* Research ethics board (REB)

Risk factors..... 138

RR. *See* Relative risks

R² statistics..... 64, 70

RTC. *See* Randomized controlled trials

S

Safety, in clinical trials..... 96

Safety monitoring. *See also* Data safety and monitoring committee

- clinical trial data..... 106

Sample sizes

- clinical trial designs..... 102–104
- diagnostic biomarkers..... 148

estimation	7, 30
prognostic biomarkers.....	145–146
Scale construction, qualitative database in.....	211–215
Schedule for the evaluation of individual quality of life (SEIQoL).....	163
Search strategy, designing.....	269
Selection bias.....	24–25, 173. <i>See also</i> Bias, in clinical epidemiologic studies
ascertainment bias	173–174
competing risks and volunteer bias	174–175
nonresponse and loss to follow-up bias.....	175
prevalence-incidence (Neyman) bias	175–176
survivor treatment selection and overmatching bias	176
Self-selection bias. <i>See</i> Volunteer bias	
SF-6D, derivative measure	161
Short Form-36(SF-36) Health Survey.....	160–161
Single-nucleotide markers	192, 195
genotyping for association-based studies.....	197
SNPs. <i>See</i> Single-nucleotide markers	
Sponsorship, for guideline development and implementation.....	256–257
Staffing. <i>See</i> Personnel	
Standardization of training, methods, and protocol	108
Standard link functions and inverses	63
Statements, guideline rules for use of.....	253
Statistical methods and results, reporting of.....	58
fit component	59
point estimates.....	59
special checking, model's requirement	59
variability in response	60
Statistical model	
appropriate model to fit data assumption verification and model specification check	47
components of.....	46
critical violations of.....	45
exposure-response relationship	47–48
fit portion of linear model	46
information gain and residual variance	50
meanings, model fitted to data	49–50
multidimensional consequences and inputs	51
multivariable analysis.....	50
random component of model	48–49
transformation of data	49
Statistical significance.....	2, 11, 31, 124, 144, 149
Steering committee, for clinical trial management	109
Stratification, in confounding improvement.....	183
Stratified design.....	98, 122–123
Study design	
examples of.....	12
structure.....	10
Study power (1 — beta error).....	7, 31
Subgroup analysis, of clinical trial	106
Substantive theory generation, grounded theory in	206–211
Surrogate outcomes	27, 138, 149–153, 243, 253
Surveillance bias. <i>See</i> Diagnostic bias	
Survival analysis.....	143
forms of.....	76
key requirements for	74–75
Survival data, study of.....	74
Survival time.....	74, 77, 85, 91, 145, 177
Systematic review. <i>See also</i> Literature review and meta-analysis	
advantages of	220–222
limitations of.....	222–223
scientific quality assessment.....	223–229
and narrative reviews, difference of.....	218–220
to synthesize data in HTA.....	272
T	
Target population	5
Technical efficiency	237, 238, 241, 299
Time-to-event data, functions of.....	75–76
Traditional method. <i>See</i> Recombinant-based method	
Treatment period.....	104
Treat-to-goal clinical study.....	2
Tri-Council Policy Statement (TCPS).....	287
risks and benefits, review of.....	290
Trio design, in family association studies.....	197
t Test.....	65, 66
Tuskegee study	286
U	
Utility, define.....	273
V	
Validation of biomarkers.....	141–149
Validity of study.....	8
external and internal	10–11
Variables	
confounding.....	26, 29
interacting.....	53
types of.....	7–8
Variance-corrected models.....	89, 91. <i>See also</i> Extended generalized linear models
Volunteer bias	174–175
Vulnerable populations, in ethical research.....	286, 295
W	
Willingness to pay method.....	239
Will Rogers phenomenon	178–179
Z	
Z value.....	32, 194